help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2005-2639
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allolio, B.
Right arrow Articles by Fassnacht, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allolio, B.
Right arrow Articles by Fassnacht, M.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 6 2027-2037
Copyright © 2006 by The Endocrine Society

CLINICAL REVIEW

Adrenocortical Carcinoma: Clinical Update

Bruno Allolio and Martin Fassnacht

Endocrinology and Diabetes Unit, Department of Medicine I, University Hospital Wuerzburg, 97080 Wuerzburg, Germany

Address all correspondence and requests for reprints to: Bruno Allolio, M.D., Endocrinology and Diabetes Unit, Department of Medicine I, University Hospital Wuerzburg, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany. E-mail: allolio_b@medizin.uni-wuerzburg.de; or fassnacht_m{at}medizin.uni-wuerzburg.de.

Context: Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with incompletely understood pathogenesis and poor prognosis. Patients present with hormone excess (e.g. virilization, Cushing’s syndrome) or a local mass effect (median tumor size at diagnosis > 10 cm). This paper reviews current diagnostic and therapeutic strategies in ACC.

Evidence Acquisition: Original articles and reviews were identified using a PubMed search strategy (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) covering the time period up until November 2005. The following search terms were used in varying combinations: adrenal, adrenocortical, cancer, carcinoma, tumor, diagnosis, imaging, treatment, radiotherapy, mitotane, cytotoxic, surgery.

Evidence synthesis: Tumors typically appear inhomogeneous in both computerized tomography and magnetic resonance imaging with necroses and irregular borders and differ from benign adenomas by their low fat content. Hormonal analysis reveals evidence of steroid hormone secretion by the tumor in the majority of cases, even in seemingly hormonally inactive lesions. Histopathology is crucial for the diagnosis of malignancy and may also provide important prognostic information. In stages I–III open surgery by an expert surgeon aiming at an R0 resection is the treatment of choice. Local recurrence is frequent, particularly after violation of the tumor capsule. Surgery also plays a role in local tumor recurrence and metastatic disease. In patients not amenable to surgery, mitotane (alone or in combination with cytotoxic drugs) remains the treatment of choice. Monitoring of drug levels (therapeutic range 14–20 mg/liter) is mandatory for optimum results. In advanced disease, the most promising therapeutic options (etoposide, doxorubicin, cisplatin plus mitotane, and streptozotocin plus mitotane) are currently being compared in an international phase III trial (www.firm-act.org). Adjuvant treatment options after complete tumor removal (e.g. mitotane, radiotherapy) are urgently needed because postoperative disease-free survival at 5 yr is only around 30%, but options have still not been convincingly established. National registries, international cooperations, and trials provide important new structures for patients but also for researchers aiming at systematic and continuous progress in ACC. However, future advances in the management of ACC will mainly depend on a better understanding of the molecular pathogenesis facilitating the use of modern cancer treatments (e.g. tyrosine kinase inhibitors).




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Tacon, P. S. Soon, A. J. Gill, A. S. Chou, A. Clarkson, J. Botling, P. L. H. Stalberg, B. M. Skogseid, B. G. Robinson, S. B. Sidhu, et al.
The Glucocorticoid Receptor Is Overexpressed in Malignant Adrenocortical Tumors
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4591 - 4599.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Terzolo, G. Reimondo, and A. Angeli
Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research
Eur. J. Endocrinol., October 1, 2009; 161(4): 529 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. L Ronchi, S. Sbiera, L. Kraus, S. Wortmann, S. Johanssen, P. Adam, H. S Willenberg, S. Hahner, B. Allolio, and M. Fassnacht
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy
Endocr. Relat. Cancer, September 1, 2009; 16(3): 907 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
W. Fenske, H.-U. Volker, P. Adam, S. Hahner, S. Johanssen, S. Wortmann, M. Schmidt, M. Morcos, H.-K. Muller-Hermelink, B. Allolio, et al.
Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma
Endocr. Relat. Cancer, September 1, 2009; 16(3): 919 - 928.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. K. Johnsen, R. Kappler, C. J. Auernhammer, and F. Beuschlein
Bone Morphogenetic Proteins 2 and 5 Are Down-regulated in Adrenocortical Carcinoma and Modulate Adrenal Cell Proliferation and Steroidogenesis
Cancer Res., July 15, 2009; 69(14): 5784 - 5792.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Terzolo, M. Fassnacht, G. Ciccone, B. Allolio, and A. Berruti
Adjuvant Mitotane for Adrenocortical Cancer--Working through Uncertainty
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1879 - 1880.
[Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
F Castinetti, M Fassnacht, S Johanssen, M Terzolo, P Bouchard, P Chanson, C Do Cao, I Morange, A Pico, S Ouzounian, et al.
Merits and pitfalls of mifepristone in Cushing's syndrome
Eur. J. Endocrinol., June 1, 2009; 160(6): 1003 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
S. Chalasani, H. S. Vats, T. K. Banerjee, and A. K. McKenzie
Metastatic Virilizing Adrenocortical Carcinoma: A Rare Case of Cure with Surgery and Mitotane Therapy
Clin. Med. Res., June 1, 2009; 7(1-2): 48 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. C. Kim, F. M. Barlaskar, J. H. Heaton, T. Else, V. R. Kelly, K. T. Krill, J. O. Scheys, D. P. Simon, A. Trovato, W.-H. Yang, et al.
In Search of Adrenocortical Stem and Progenitor Cells
Endocr. Rev., May 1, 2009; 30(3): 241 - 263.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. de Reynies, G. Assie, D. S. Rickman, F. Tissier, L. Groussin, F. Rene-Corail, B. Dousset, X. Bertagna, E. Clauser, and J. Bertherat
Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival
J. Clin. Oncol., March 1, 2009; 27(7): 1108 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J.-O. Lee, K.-W. Lee, C.-J. Kim, Y. J. Kim, H. E. Lee, H. Kim, J. H. Kim, S.-M. Bang, J.-S. Kim, and J. S. Lee
Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report
Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 183 - 185.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. M. Barlaskar, A. C. Spalding, J. H. Heaton, R. Kuick, A. C. Kim, D. G. Thomas, T. J. Giordano, E. Ben-Josef, and G. D. Hammer
Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 204 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
C. Rodriguez-Galindo, G. Zambetti, and R. C. Ribeiro
Epidemiology, Clinical Characteristics, and Treatment of Childhood Adrenocortical Tumors
ASCO Educational Book, January 1, 2009; 2009(1): 625 - 629.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
P K Singh and H N Buch
Adrenal incidentaloma: evaluation and management
J. Clin. Pathol., November 1, 2008; 61(11): 1168 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al.
Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A Advani, S Vaikkakara, M S Gill, C S Arun, S H Pearce, S G Ball, R A James, T W J Lennard, R D Bliss, R Quinton, et al.
Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review
J. Clin. Pathol., August 1, 2008; 61(8): 939 - 944.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L Cerquetti, B Bucci, R Marchese, S Misiti, U De Paula, R Miceli, A Muleti, D Amendola, P Piergrossi, E Brunetti, et al.
Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines
Endocr. Relat. Cancer, June 1, 2008; 15(2): 623 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht
Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Hahner, A. Stuermer, M. Kreissl, C. Reiners, M. Fassnacht, H. Haenscheid, F. Beuschlein, M. Zink, K. Lang, B. Allolio, et al.
[123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2358 - 2365.
[Abstract] [Full Text] [PDF]

Home page
 Ann Clin BiochemHome page
S. Hancock, R. A Still, A. M Fielding, J. F Doran, and J. W Stephens
A rare cause of Cushing's syndrome demonstrates analytical discrepancies between the Roche E170 and Bayer Centaur testosterone assays
Ann Clin Biochem, May 1, 2008; 45(3): 328 - 330.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu
Molecular Markers and the Pathogenesis of Adrenocortical Cancer
Oncologist, May 1, 2008; 13(5): 548 - 561.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Else, T. J. Giordano, and G. D. Hammer
Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1442 - 1449.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
U. D. Lichtenauer, I. Shapiro, K. Geiger, M. Quinkler, M. Fassnacht, R. Nitschke, K.-D. Ruckauer, and F. Beuschlein
Side Population Does Not Define Stem Cell-Like Cancer Cells in the Adrenocortical Carcinoma Cell Line NCI h295R
Endocrinology, March 1, 2008; 149(3): 1314 - 1322.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Bertherat, J. Coste, X. Bertagna, G. Dickstein, C. Shechner, O. Nativ, J. E. Lee, A. Machens, H. Dralle, M. Terzolo, et al.
Adjuvant Mitotane in Adrenocortical Carcinoma
N. Engl. J. Med., September 20, 2007; 357(12): 1256 - 1259.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A Carmona-Bayonas, I. Soler, F. Gomez, E. Billalabeitia, H. Saura, M. Tafalla, and M. Diaz
Tailored hormonal therapy in secretory adrenocortical cancer
Ann. Onc., July 1, 2007; 18(7): 1281 - 1281.
[Full Text] [PDF]

Home page
 NEJMHome page
M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al.
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. F. Young Jr.
The Incidentally Discovered Adrenal Mass
N. Engl. J. Med., February 8, 2007; 356(6): 601 - 610.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Libe, L. Groussin, F. Tissier, C. Elie, F. Rene-Corail, A. Fratticci, E. Jullian, P. Beck-Peccoz, X. Bertagna, C. Gicquel, et al.
Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity
Clin. Cancer Res., February 1, 2007; 13(3): 844 - 850.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Assie, G. Antoni, F. Tissier, B. Caillou, G. Abiven, C. Gicquel, S. Leboulleux, J.-P. Travagli, C. Dromain, X. Bertagna, et al.
Prognostic Parameters of Metastatic Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 148 - 154.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. S. Kirschner
Paradigms for adrenal cancer: think globally, act locally.
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4250 - 4252.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Fassnacht, S. Hahner, B. Polat, A.-C. Koschker, W. Kenn, M. Flentje, and B. Allolio
Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4501 - 4504.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society